The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Brazil play their next World Cup qualifier against Peru on the road on Tuesday night (local time).Ahead of the game, there is ...

Peripheral edema, particularly of the lower limbs, is one of the most common adverse effects of dihydropyridine calcium channel blockers and may result in the need for dose reduction or drug ...

Ganduje, governors and party leaders at various levels were in Akure, the Ondo State capital, on Sunday, to galvanise support ...

The Global Edema Clinical Trials Market is valued at approximately USD 877.31 million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.7% over the forecast period 2024-2032 ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

Diabetic macular edema (DME) is a complication of diabetic retinopathy. It occurs when fluid builds up in the macula, the center portion of the retina. The retina is the layer of cells at the back of ...

Roche (RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo ...

Christina Y Weng, MD, MBA sat down to discuss the Retina Ophthalmic Technology Assessment Symposium and her journal on ...

Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of ...

Calcium channel blocker (CCB)-related edema is quite common in clinical practice and can effectively deter a clinician from continued prescription of these drugs. Its etiology relates to a ...